

Marie E Wood

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5293119/publications.pdf>

Version: 2024-02-01

33
papers

1,038
citations

687363

13
h-index

501196

28
g-index

34
all docs

34
docs citations

34
times ranked

1659
citing authors

#	ARTICLE	IF	CITATIONS
1	Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 63-70.	1.8	1
2	Quantitative Assessment of Learning Behaviors for Oncology Providers. <i>Journal of Cancer Education</i> , 2021, 36, 25-32.	1.3	1
3	Establishing and Evaluating an ASCO Learning Cohort: a Longitudinal Project Assessing the Learning Needs and Behaviors of Oncology Professionals. <i>Journal of Cancer Education</i> , 2021, 36, 478-483.	1.3	0
4	The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial. <i>Cancer Prevention Research</i> , 2021, 14, 753-762.	1.5	8
5	Identifying key barriers to effective breast cancer control in rural settings. <i>Preventive Medicine</i> , 2021, 152, 106741.	3.4	20
6	Importance of family history and indications for genetic testing. <i>Breast Journal</i> , 2020, 26, 100-104.	1.0	13
7	Risk for breast cancer and management of unaffected individuals with non- ϵ BRCA hereditary breast cancer. <i>Breast Journal</i> , 2020, 26, 1528-1534.	1.0	20
8	Effect of neuromuscular electrical stimulation on skeletal muscle size and function in patients with breast cancer receiving chemotherapy. <i>Journal of Applied Physiology</i> , 2020, 128, 1654-1665.	2.5	15
9	Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. <i>Breast Journal</i> , 2019, 25, 575-577.	1.0	3
10	Increasing Adherence to Adjuvant Hormone Therapy Among Patients With Breast Cancer: A Smart Phone App-Based Pilot Study. <i>Cancer Control</i> , 2019, 26, 107327481988328.	1.8	23
11	Towards a more precise and individualized assessment of breast cancer risk. <i>Aging</i> , 2019, 11, 1305-1316.	3.1	9
12	Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11. <i>Human Mutation</i> , 2018, 39, 515-526.	2.5	5
13	Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 427-432.	2.4	11
14	Placing negative multi-gene panel results into clinical context. <i>Familial Cancer</i> , 2017, 16, 595-595.	1.9	0
15	Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. <i>Familial Cancer</i> , 2017, 16, 159-166.	1.9	16
16	Development of a predictive miRNA signature for breast cancer risk among high-risk women. <i>Oncotarget</i> , 2017, 8, 112170-112183.	1.8	30
17	Family history matters. <i>Cancer</i> , 2016, 122, 2618-2620.	4.1	1
18	Contribution of extended family history in assessment of risk for breast and colon cancer. <i>BMC Family Practice</i> , 2016, 17, 126.	2.9	13

#	ARTICLE	IF	CITATIONS
19	The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women. <i>Cancer Prevention Research</i> , 2016, 9, 379-384.	1.5	19
20	Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. <i>American Journal of Hematology/oncology</i> , 2016, 12, 4-9.	0.0	4
21	Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. <i>Genetics in Medicine</i> , 2015, 17, 467-475.	2.4	86
22	Comparison of false positive rates for screening breast magnetic resonance imaging (MRI) in high risk women performed on stacked versus alternating schedules. <i>SpringerPlus</i> , 2015, 4, 77.	1.2	19
23	Ductal Carcinoma In Situ: A Brief Review of Treatment Variation and Impacts on Patients and Society. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2014, 24, 281-286.	0.9	11
24	Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. <i>Journal of Clinical Oncology</i> , 2014, 32, 824-829.	1.6	146
25	American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers. <i>Journal of Clinical Oncology</i> , 2014, 32, 833-840.	1.6	210
26	Low-dose metronomic cyclophosphamide/methotrexate (LDCM) and aspirin for patients who fail to achieve pathologic complete response (pCR) after neoadjuvant treatment for stage II-III breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e12000-e12000.	1.6	0
27	Change in mammographic density with metformin use: A companion study to NCIC study MA.32.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1608-TPS1608.	1.6	0
28	Low-dose metronomic cyclophosphamide/methotrexate (LDCM) and aspirin for patients without pathologic complete response (pCR) after neoadjuvant treatment for stage II-III breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 163-163.	1.6	1
29	Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. <i>Journal of Clinical Oncology</i> , 2012, 30, 3734-3745.	1.6	263
30	Discrepancy Between Preference and Actual Adjuvant Therapy for Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 398-403.	2.4	1
31	Ductal Lavage of Cancerous and Unaffected Breasts. <i>Acta Cytologica</i> , 2009, 53, 410-415.	1.3	7
32	Interviews with primary care physicians regarding taking and interpreting the cancer family history. <i>Family Practice</i> , 2008, 25, 334-340.	1.9	70
33	Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the) <i>Tj ETQq1 1 0.784314 rgBT /Ove</i>	2.1	92